ECSP11011307A - Comprimidos para terapia de combinacion - Google Patents

Comprimidos para terapia de combinacion

Info

Publication number
ECSP11011307A
ECSP11011307A EC2011011307A ECSP11011307A ECSP11011307A EC SP11011307 A ECSP11011307 A EC SP11011307A EC 2011011307 A EC2011011307 A EC 2011011307A EC SP11011307 A ECSP11011307 A EC SP11011307A EC SP11011307 A ECSP11011307 A EC SP11011307A
Authority
EC
Ecuador
Prior art keywords
tablets
combination therapy
formula
compound
salt
Prior art date
Application number
EC2011011307A
Other languages
English (en)
Inventor
Joanna M Koziara
Mark M Menning
Reza Oliyai
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41722740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011307(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of ECSP11011307A publication Critical patent/ECSP11011307A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona formas farmaceuticas sólidas (por ejemplo comprimidos) que comprende un compuesto de Formula I, un compuesto de Formula II, un compuesto de Formula III y una sal de Formula IV.
EC2011011307A 2009-02-06 2011-09-06 Comprimidos para terapia de combinacion ECSP11011307A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15065209P 2009-02-06 2009-02-06
US15065509P 2009-02-06 2009-02-06

Publications (1)

Publication Number Publication Date
ECSP11011307A true ECSP11011307A (es) 2011-10-31

Family

ID=41722740

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011307A ECSP11011307A (es) 2009-02-06 2011-09-06 Comprimidos para terapia de combinacion

Country Status (30)

Country Link
US (2) US20100285122A1 (es)
EP (1) EP2393485B1 (es)
JP (2) JP5611242B2 (es)
KR (2) KR101645759B1 (es)
CN (1) CN102307573B (es)
AP (1) AP3250A (es)
AR (1) AR075369A1 (es)
AU (1) AU2010210598B2 (es)
BR (1) BRPI1008664A2 (es)
CA (1) CA2750521A1 (es)
CL (1) CL2011001885A1 (es)
CY (1) CY1116852T1 (es)
DK (1) DK2393485T3 (es)
EA (2) EA021313B1 (es)
EC (1) ECSP11011307A (es)
ES (1) ES2548886T3 (es)
HR (1) HRP20151009T1 (es)
HU (1) HUE025822T2 (es)
IL (1) IL214227A (es)
MX (1) MX2011008289A (es)
NZ (1) NZ594214A (es)
PE (1) PE20110994A1 (es)
PL (1) PL2393485T3 (es)
PT (1) PT2393485E (es)
SG (3) SG173544A1 (es)
SI (1) SI2393485T1 (es)
SM (1) SMT201500266B (es)
TW (1) TWI444367B (es)
UY (1) UY32424A (es)
WO (1) WO2010091197A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2049506T2 (sl) 2006-07-07 2024-07-31 Gilead Sciences, Inc. Modulatorji farmakokinetičnih lastnosti terapevtikov
EP4403221A3 (en) * 2007-02-23 2024-10-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
CN103479584A (zh) 2008-05-02 2014-01-01 吉里德科学公司 固体载体颗粒在改善药物制剂加工性中的应用
TWI556840B (zh) 2010-11-19 2016-11-11 吉李德科學股份有限公司 治療用組成物
WO2012072580A1 (en) * 2010-11-29 2012-06-07 Formac Pharmaceuticals N.V. Compressed formulations of ordered mesoporous silicas
SI2729130T1 (en) * 2011-07-07 2018-03-30 Janssen Sciences Ireland Uc Combined formulations of darunavir
CN110343135A (zh) 2011-08-16 2019-10-18 吉利德科学公司 替诺福韦艾拉酚胺(tenofovir alafenamide)半反丁烯二酸盐
WO2013115916A1 (en) * 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections
MD20140091A2 (ro) * 2012-02-03 2015-01-31 Gilead Sciences, Inc. Terapie combinată cuprinzând hemifumarat tenofovir alafenamidă şi cobicistat pentru utilizare în tratamentul infecţiilor virale
JP2015508822A (ja) * 2012-03-01 2015-03-23 ギリアード サイエンシーズ， インコーポレイテッド 噴霧乾燥製剤
CN103830192A (zh) * 2012-11-27 2014-06-04 安徽贝克生物制药有限公司 一种可粉末直接压片的富马酸替诺福韦二吡呋酯片剂及制备方法
CA2893843C (en) 2012-12-21 2018-09-04 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EA201792592A1 (ru) 2015-06-30 2018-06-29 Джилид Сайэнс, Инк. Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
SI3346995T1 (sl) 2015-11-09 2019-11-29 Gilead Sciences Inc Terapevtski sestavek za zdravljenje virusa človeške imunske pomanjkljivosti
WO2017134089A1 (en) 2016-02-02 2017-08-10 Sandoz Ag Crystalline forms of tenofovir alafenamide monofumarate
WO2022034232A1 (en) * 2020-08-13 2022-02-17 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Gastro-resistant high-strength formulation containing posaconazole

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
DE10153078A1 (de) * 2001-10-30 2003-05-22 Degussa Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
JP3567162B1 (ja) * 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
CN100375742C (zh) * 2002-11-20 2008-03-19 日本烟草产业株式会社 4-氧代喹啉化合物及其用途
WO2004046115A1 (ja) 2002-11-20 2004-06-03 Japan Tobacco Inc. ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
EA015145B1 (ru) 2003-01-14 2011-06-30 Джилид Сайэнс, Инк. Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
US20080317852A1 (en) * 2005-12-14 2008-12-25 Amar Lulla Pharmaceutical Combination
SI2049506T2 (sl) 2006-07-07 2024-07-31 Gilead Sciences, Inc. Modulatorji farmakokinetičnih lastnosti terapevtikov
EP4403221A3 (en) 2007-02-23 2024-10-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics

Also Published As

Publication number Publication date
ES2548886T3 (es) 2015-10-21
CY1116852T1 (el) 2017-04-05
IL214227A0 (en) 2011-09-27
SMT201500266B (it) 2016-01-08
EA021313B1 (ru) 2015-05-29
EP2393485B1 (en) 2015-07-29
CA2750521A1 (en) 2010-08-12
HK1164737A1 (en) 2012-09-28
AU2010210598B2 (en) 2015-03-05
TW201040142A (en) 2010-11-16
BRPI1008664A2 (pt) 2016-03-08
JP5611242B2 (ja) 2014-10-22
US20100285122A1 (en) 2010-11-11
UY32424A (es) 2010-09-30
EA201190125A1 (ru) 2012-01-30
SG173544A1 (en) 2011-09-29
AP2011005857A0 (en) 2011-10-31
NZ594214A (en) 2013-05-31
EA030123B1 (ru) 2018-06-29
KR101738325B1 (ko) 2017-05-19
AU2010210598A1 (en) 2011-08-25
US20150150810A1 (en) 2015-06-04
JP2014221845A (ja) 2014-11-27
KR20160093100A (ko) 2016-08-05
KR101645759B1 (ko) 2016-08-04
AP3250A (en) 2015-05-31
CN102307573A (zh) 2012-01-04
CL2011001885A1 (es) 2012-05-25
DK2393485T3 (en) 2015-10-26
EP2393485A2 (en) 2011-12-14
WO2010091197A2 (en) 2010-08-12
HRP20151009T1 (hr) 2015-10-23
PT2393485E (pt) 2015-10-23
PL2393485T3 (pl) 2015-12-31
CN102307573B (zh) 2013-09-11
KR20110122729A (ko) 2011-11-10
AR075369A1 (es) 2011-03-30
SG10201706215UA (en) 2017-08-30
TWI444367B (zh) 2014-07-11
SG2014007744A (en) 2014-05-29
PE20110994A1 (es) 2012-01-24
SI2393485T1 (sl) 2015-10-30
EA201491658A1 (ru) 2015-05-29
IL214227A (en) 2017-01-31
JP2012517432A (ja) 2012-08-02
HUE025822T2 (en) 2016-04-28
JP5911927B2 (ja) 2016-04-27
MX2011008289A (es) 2011-09-15
WO2010091197A3 (en) 2011-06-03

Similar Documents

Publication Publication Date Title
UY32424A (es) Comprimidos conteniendo elivitegravir para tratamiento de infecciones virales
CO6511251A2 (es) Compuestos quimicos
EA201200550A1 (ru) Фармацевтические композиции, включающие bi-1356 и метформин
CL2011001254A1 (es) Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente a cd38 y al menos melfalan; y su uso para el tratamiento contra el cancer.
SV2011004061A (es) Aril-piridinas como inhibidores de sintasa de aldosterona
CL2008000691A1 (es) Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades.
MX2012006233A (es) Nuevos compuestos de espiropiperidina.
MY163083A (en) Solid forms of a pharmaceutically active substance
BRPI1008498A2 (pt) Composto, prodroga do composto, medicamento, e, uso de um composto.
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
CL2007003138A1 (es) Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
UY32535A (es) Métodos e intermediarios para la preparación de agentes farmacéuticos
EA201001710A3 (ru) Фармацевтическая композиция, которая содержит соль стронция, витамин d и циклодекстрин
CL2008003041A1 (es) Compuestos derivados de acido boronico, inhibidores de proteasoma; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
HN2008001723A (es) Nitrilos espirociclicos como inhibidores de proteasa
CR11740A (es) Composiciones que comprenden fármacos levemente básicos y formas de dosificación de liberación controlada
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
ES2415029R1 (es) Composición farmacéutica y método para inhibir la producción o amplificar la eliminación de la proteína P24.
EA201171414A1 (ru) Ингибиторы белков семейства iap